Anticholinergic drug abuse and misuse: Epidemiology and therapeutic implications

CNS Drugs

Volumn 5, Issue 3, 1996, Pages 190-199

  Marken, Patricia A ^a,b,c   Stoner, Steven C ^a,c   Bunker, Mark T ^a,c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c W Missouri Mental Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPHENHYDRAMINE; ORPHENADRINE; PROCYCLIDINE; TRIHEXYPHENIDYL;

ADULT; DRUG ABUSE; EUPHORIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERSONALITY DISORDER; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 0029865639     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605030-00005     Document Type: Review

References (47)

1. Brown JH. Atropine, scopolamine and related antimuscarinic drugs. In: Goodman Gilman A, Rall TW, Neis AS, et al., editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamon Press Inc., 1990: 150-67
2. Bolin RR. Psychiatric manifestation of Artane toxicity. J Nerv Ment Dis 1960; 131: 256-9
3. Crawshaw JA, Mullen PE. A study of benzhexol abuse. Br J Psychiatry 1984; 145: 300-3
4. McEvoy GK, editor. American hospital. Formulary Service drug information 95. Bethesda: American Society of Health System Pharmacists, 1995
5. Dugas JE. Mood elevation and medication [letter]. Dis Nerv Syst 1977; 38: 958
6. Golf DC, Baldessarini RJ. Drug interactions with antipsychotics. J Clin Psychopharmacol 1993; 13: 57-67
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
8. Buckley P, Larkin C, O'Callaghan E. Psychosis following use of proprietary antidiarrhoeal medicines. Br J Psychiatry 1990; 157: 758-4
9. Craig DH, Rosen P. Abuse of antiparkinsonian drugs. Ann Emerg Med 1981; 10: 98-100
10. Deutsch A, Eyma J. Massive ingestion of trihexyphenidyl [letter]. Am J Psychiatry 1992; 149: 574-5
11. Fisch RZ. Trihexyphenidyl abuse: therapeutic implications for negative symptoms of schizophrenia? Acta Psychiatr Scand 1987; 75: 91-4
12. Goggin DA. Trihexyphenidyl abuse tor euphorigenic effect. Am J Psychiatry 1979; 136: 459-60
13. Harrison G. The abuse of anticholinergic drugs in adolescents [letter]. Br J Psychiatry 1980; 137: 495
14. Jellinek T. Mood elevating effect of trihexyphenidyl and biperiden in individuals taking antipsychotic medication. Dis Nerv Syst 1977; 38: 353-5
15. Johnson AL, Hollister LE, Berger PA. The anticholinergic intoxication syndrome: diagnosis and treatment. J Clin Psychiatry 1981; 42: 313-7
16. Kaminer Y, Munitz H, Wijsenbeek H. Trihexyphenidyl (Artane) abuse: euphoriant and anxiolytic. Br J Psychiatry 1982; 140: 473-4
17. Macvicar K. Abuse of antiparkinsonian drugs by psychiatric patients. Am J Psychiatry 1977; 134: 809-11
18. Pullen GP, Best NR, Maguire J. Anticholinergic drug abuse: a common problem? BMJ 1984; 289: 612-3
19. Rubinstein JS. Antiparkinsonian drug abuse: eight case reports. Hosp Community Psychiatry 1979; 30: 34-7
20. Sofair J, Campion J, Angrist B. High dose trihexyphenidyl abuse with psychological dependence [letter]. J Clin Psychopharmacol 1983; 3: 263-4
21. Wells BG, Marken PA, Rickman LA, et al. Characterizing anticholinergic abuse in community mental health. J Clin Psychopharmacol 1989; 9: 431-5
22. Woody GE, O'Brien CP. Anticholinergic toxic psychosis in drug abusers treated with henztropine. Compr Psychiatry 1974; 15: 439-42
23. Sato EH, Freitas DD, Foster CS. Abuse of cyclopentolate hydrochloride (Cyclogyl) drops [letter]. N Engl J Med 1992; 326: 1363-4
24. Buckley P, Larkin C, O'Callaghan E. Psychosis following use of proprietary antidiarrhoeal medicines. Br J Psychiatry 1990; 157: 758-9
25. Delisle J. A case of amitriptyline abuse [letter]. Am J Psychiatry 1990; 147: 1377-8
26. Marriott P. Dependence on antiparkinsonian drugs [letter]. BMJ 1976; 17: 1152
27. Land W, Pinsky D, Salzman C. Abuse and misuse of anticholinergic medications. Hosp Community Psychiatry 1991; 42: 580-1
28. Dilsaver SC. Antimuscarinic agents as substances of abuse: a review. J Clin Psychopharmacol 1988; 8: 14-22
29. Rubinstein JS. Abuse of antiparkinsonism drugs: feigning of extrapyramidal symptoms to obtain trihexyphenidyl. JAMA 1978; 239: 2365-6
30. Saran AS. Use or abuse of antiparkinsonian drugs by psychiatric patients. J Clin Psychiatry 1986; 47: 130-2
31. Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Psychiatr Clin North Am 1993; 16: 589-610
32. Smith JM. Abuse of antiparkinson drugs: a review of the literature. J Clin Psychiatry 1980; 41: 351-4
33. Siris SG. Akinesia and postpsychotic depression: a difficult differential diagnosis. J Clin Psychiatry 1987; 48: 240-3
34. Tandon R, Greeden JF, Silk KR. Treatment of negative schizophrenic symptoms with trihexyphenidyl. J Clin Psychopharmacol 1989; 8: 212-5
35. Janowsky DS, El-Yousef MK, Davis JM, et al. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972; 2: 632-5
36. Janowsky DS, Overstreet DH. The role of acetylcholine mechanisms in mood disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 945-56
37. McGlashan TH, Carpenter WT. Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 1976; 33: 231-41
38. Siever LJ, Risch SC, Murphy DL. Central cholinergic-adrenergic imbalance in the regulation of affective state. Psychiatry Res 1981; 5: 108-9
39. Tandon R, Greeden JF. Cholinergic hyperactivity and negative schizophrenic symptoms: a model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 1989; 46: 745-53
40. Johnstone EC, Crowe TJ, Ferrier IN. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychiatr Med 1983; 13: 513-27
41. Goff DC, Amico E, Dreyfuss E, et al. A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia. Am J Psychiatry 1994; 151: 429-31
42. Tandon R, DeQuardo, JR. Treatment of schizophrenia with anticholinergic medications [letter]. Am J Psychiatry 1995; 152: 814-5
43. World Health Organization Heads of Centers Collaborating in WHO Coordinated Studies on the Biological. Aspects of mental illness. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. Br J Psychiatry 1990; 156: 412-4
44. Barnes TRE. Comment on the WHO consensus statement. Br J Psychiatry 1990; 156: 413-4
45. Tune LE, Strauss ME, Lew MF, et al. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982; 139: 1460-2
46. Krammer JC, Cline DF, Fink FM. Withdrawal symptoms following discontinuation of imipramine therapy. Am J Psychiatry 1961; 118: 549-50
47. Dilsaver SC, Greden JF. Antidepressant withdrawal phenomena. Biol Psychiatry 1984; 19: 237-56